2/21/2008

Pfizer on Wednesday announced it intends to acquire Encysive Pharmaceuticals in a $195 million deal that would grant it rights to Thelin, Encysive's treatment for pulmonary arterial hypertension. Thelin is still struggling to obtain FDA approval, but Pfizer's expertise in the market for such treatments is likely to boost the chances of drug candidate to gain regulatory clearance, an analyst said.

Related Summaries